FindTrial
Sign In

Vitamin D3 fortified antihypertensive as an effective treatment for hypertension in stroke

Exploring the effects of Vitamin D fortified Telmisartan in ishchaemic stroke patients : A novel therapeutic approach - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078239
Enrollment
60
Registered
2024-12-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G819- Hemiplegia, unspecified

Interventions

Intervention1: A new formulation of Vitamin D3 (600 IU) fortified Telimsartan (40mg) in ischaemic stroke patients: A new formulation of Vitamin D3 (600 IU) fortified Telimsartan (40mg) in ischaemic st

Sponsors

SAVEETHA MEDICAL COLLEGE AND HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosis: Confirmed diagnosis of acute ischemic stroke based on neuroimaging (e.g., CT scan or MRI) performed within the past 48 hours. 2.Informed Consent: Ability to provide informed consent either directly or through a legally authorized representative. 3.Time Window: Presentation within the acute phase of ischemic stroke (within 48 hours of symptom onset). 4.Neurological Deficit: Presence of neurological deficits consistent with ischemic stroke, such as hemiparesis, hemiplegia, aphasia, or visual field deficits. 5.Hemodynamic Stability: Stable hemodynamic parameters without the need for vasopressor support. 6.Provision of Follow-up: Willingness and ability to participate in follow-up assessments as required by the study protocol. 7.Compliance: Willingness and ability to comply with the study procedures, including medication adherence and attendance at scheduled study visits.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Functional outcome assessed by modified Rankin Scale (mRS) at 3 months post-stroke.Timepoint: Functional outcome assessed by modified Rankin Scale (mRS) at 3 months post-stroke.—

Secondary

MeasureTime frame
? Neurological recovery assessed by National Institutes of Health Stroke Scale (NIHSS) at 7 days and 90 days. ? Incidence of recurrent stroke or vascular events at 90 days. ? Safety endpoints including incidence of adverse events, changes in blood pressure, serum calcium levels, and renal function. ? Biomarker analysis to investigate the mechanistic effects of vitamin D fortified telmisartan on stroke pathology. Timepoint: 90 DAYS—

Countries

India

Contacts

Public ContactShrinidhi B
shrinidhib09@gmail.com9597330433

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026